Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin Dosing for VTE Prophylaxis Post-Cesarean
NCT04305756Completed
- Sponsor
- University of Utah
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by University of Utah. Primary endpoint: Peak anti-factor Xa level. Started Jun 2020; status: completed.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04305756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305756.